Related Experiment Video
Updated: Feb 5, 2026

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma
Ferga C Gleeson1, Michael J Levy2
1Division of Gastroenterology & Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Gleeson.ferga@mayo.edu.
Purpose Of Review:
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-associated mortality with continued poor outcome and a short-lived treatment response to conventional therapy. However, with the rapidly evolving field of precision oncology, new and novel genomic information is emerging, identifying tumor subtypes by revealing somatic and germline mutations.
Recent Findings:
There is growing interest in determining the tumor BRCA status to guide potential PARP inhibitor targeted therapy and for evaluating tumor microsatellite instability status for immune checkpoint inhibitor therapy which has been reported in up to 3% of PDAC patients. Precision immuno-oncology and therapies targeting the stroma are a developing oncologic field but to date the impact upon patients with PDAC has not been established. The ability to complete tumor genotyping and gene expression assessments and to determine immunotherapy eligibility have renewed optimism that patients with PDAC may soon have access to effective treatment strategies.
Insights
Pancreatic cancer (PDAC) treatment is improving with precision oncology. Genomic insights are identifying tumor subtypes and guiding targeted therapies like PARP inhibitors and immunotherapies.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited response to conventional treatments.
- Genomic advancements are revealing tumor subtypes and potential therapeutic targets.
Purpose of the Study:
- To review the emerging role of precision oncology in identifying novel genomic information for PDAC treatment.
- To explore the impact of tumor genotyping and gene expression assessments on treatment strategies.
Main Methods:
- Review of current research in precision oncology for PDAC.
- Analysis of emerging genomic data, including somatic and germline mutations.
- Evaluation of tumor BRCA status and microsatellite instability.
Main Results:
- Growing interest in BRCA status for PARP inhibitor therapy.
- Identification of microsatellite instability in up to 3% of PDAC patients for immunotherapy.
- Tumor genotyping and gene expression assessments offer new treatment avenues.
Conclusions:
- Precision oncology offers new hope for effective PDAC treatment strategies.
- Genomic profiling is crucial for guiding targeted therapies and immunotherapy eligibility.
- Further research is needed to establish the impact of novel therapies like immuno-oncology and stroma-targeting agents.
Related Concept Videos
Genomics
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Alterations in Blood Pressure
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Genome Size and the Evolution of New Genes

